Andy L. Chiang

Learn more from our Eureka Blog about innovative research being done to develop better in vitro techniques for studying so-called mechanical diseases, like hypertension or arrhythmias. https://okt.to/6Hhag8

1

Discover the power of QIAGEN's Human Somatic Mutation Database (HSMD) – your ultimate resource for comprehensive, up-to-date somatic mutation data. Empower your research and clinical decisions with curated insights from over 37,000 publications and 1.6 million somatic mutations. 🌟 Why choose HSMD? -QIAGEN has data from over 545,000 real-world clinical oncology cases -A minimum of 70,000 new clinical oncology cases will be added each year -HSMD contains over 1.8 million variants from the QIAGEN Knowledge Base -HSMD covers over 1,400 cancer-related genes -Extensive coverage of cancer-related somatic mutations -Expertly curated data from scientific literature -Integrated tools for easy data interpretation Join the forefront of genomic research and enhance your understanding of cancer genomics with HSMD. Start exploring today and transform data into actionable insights. 📊 https://lnkd.in/gdsX93pD #PrecisionMedicine #CancerResearch #Genomics #HSMD #QIAGEN #Bioinformatics #SomaticMutations

9

More improvements on the way... one solution for Illumina TSO500 + HRD, faster turnaround times and more..

18

Biosimilar antibodies are effective tools for investigating a drug's absorption, distribution, and metabolism. Bio X Cell offers a growing offering of biosimilar antibodies validated in a variety of applications.

9

Join us for the webinar "AI meets Chemistry: Standigm’s Breakthrough with Synthia Retrosynthesis Software" on Tuesday, December 17, 2024, at 1:00 PM EST. This session will deep dive into Standigm's innovative application of the Synthia web-app, Synthia SAS API, and Synthia full retro API, which are designed to enhance drug discovery processes through artificial intelligence. Key topics include: • How Standigm integrates Synthia’s tools to streamline the drug discovery process, improving efficiency and output. • Detailed functionalities and benefits of the Synthia web-app, SAS API, and full retro API in pharmaceutical applications. • Strategies for leveraging AI in drug discovery to identify novel drug targets and design effective molecular modulators. Speakers: Dr. Ewa Gajewska, Head of Product Management for SYNTHIA™ Retrosynthesis Software at Merck KGaA, will share insights from her extensive experience in developing computer-assisted synthetic planning tools. Dr. You Young Song, Principal AI Scientist at Standigm, will discuss the role of generative and synthesis AI in advancing drug discovery. This webinar is ideal for professionals in chemistry, biology, and AI who are interested in the application of AI technologies in pharmaceutical research. Register now to gain a deeper understanding of AI’s role in transforming drug discovery. bit.ly/49zdzPw #TeamMerck

3

Crisp IHC images that Pathologists like :-).

10

Results from the 2024 World Class RIM Study from Gens & Associates are nearly with us. Upcoming highlights: 🔹Transition of true cross-functionality (RIM, Quality, Clinical, Safety) from aspiration to reality - faster more robust decision making. 🔹Confidence in the data within those lakes (not swamps) continues to climb. 🔹Formalised continuous improvement driven by business metrics is becoming the norm. 🔹Emergence of formalized digital strategies for regulatory. #Generis, #Regulatory, #Pharma

10

Do you know when companion diagnostics (CDx) are needed for your cell and gene therapy programs? Or what kind of testing is required and how to choose the right lab partner for a CDx assay? In our blog, you’ll learn from Labcorp subject matter experts as they answer key questions you may have about developing CDx for your cell and gene therapy programs. Learn more: https://lnkd.in/gSChJieM #CellandGeneTherapy #CompanionDiagnostics

4

https://lnkd.in/etB2Pmqt : a new compound called TRanscriptional Activator of p53 (TRAP-1) is able to engage p53-Y220C and BRD4 in a ternary complex, which potently re-activates mutant p53, resulting in rapid upregulation of p21 and other p53 target genes and inhibits the growth of p53Y220C-expressing cell lines.

8

RNA-Seq performs a comprehensive assessment of gene expression pathways, implicated in cancer development, that is vital for identifying personalized treatment options for patients. Learn how Labcorp's OmniSeq INSIGHT provides insights that can pave the way for more targeted therapies: https://lnkd.in/gg9Kwgq2

6

Happy Friday all! Check out this open access Nature Scientific Reports article by Abali et al., "A nanowell platform to identify, sort and expand high antibody-producing cells." https://lnkd.in/gMuJNSxf Abstract: Increased use of therapeutic monoclonal antibodies and the relatively high manufacturing costs fuel the need for more efficient production methods. Here we introduce a novel, fast, robust, and safe isolation platform for screening and isolating antibody-producing cell lines using a nanowell chip and an innovative single-cell isolation method. An anti-Her2 antibody producing CHO cell pool was used as a model. The platform; (1) Assures the single-cell origin of the production clone, (2) Detects the antibody production of individual cells and (3) Isolates and expands the individual cells based on their antibody production. Using the nanowell platform we demonstrated an 1.8–4.5 increase in anti-Her2 production by CHO cells that were screened and isolated with the nanowell platform compared to CHO cells that were not screened. This increase was also shown in Fed-Batch cultures where selected high production clones showed titers of 19–100 mg/L on harvest day, while the low producer cells did not show any detectable anti-Her2 IgG production. The screening of thousands of single cells is performed under sterile conditions and the individual cells were cultured in buffers and reagents without animal components. The time required from seeding a single cell and measuring the antibody production to fully expanded clones with increased Her-2 production was 4–6 weeks. #drugdiscovery #antibodies #cancerresearch #immunotherapy #immunooncology #scientificresearch

11

Happy Tuesday all! Check out this open access Immunological Review by Yu et al., "Single domain antibody: Development and application in biotechnology and biopharma." Summary: Heavy-chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains-only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb). These functional HCAbs, serendipitous discovered about three decades ago, are exclusively found in camelids, comprising dromedaries, camels, llamas, and vicugnas. Nanobodies have become an essential tool in biomedical research and medicine, both in diagnostics and therapeutics due to their beneficial properties: small size, high stability, strong antigen-binding affinity, low immunogenicity, low production cost, and straightforward engineering into more potent affinity reagents. The occurrence of HCAbs in camelids remains intriguing. It is believed to be an evolutionary adaptation, equipping camelids with a robust adaptive immune defense suitable to respond to the pressure from a pathogenic invasion necessitating a more profound antigen recognition and neutralization. This evolutionary innovation led to a simplified HCAb structure, possibly supported by genetic mutations and drift, allowing adaptive mutation and diversification in the heavy chain variable gene and constant gene regions. Beyond understanding their origins, the application of nanobodies has significantly advanced over the past 30 years. Alongside expanding laboratory research, there has been a rapid increase in patent application for nanobodies. The introduction of commercial nanobody drugs such as Cablivi, Nanozora, Envafolimab, and Carvykti has boosted confidence among in their potential. This review explores the evolutionary history of HCAbs, their ontogeny, and applications in biotechnology and pharmaceuticals, focusing on approved and ongoing medical research pipelines. #drugdiscovery #nanobodies #cancerresearch #therapeutics #immunology #antibodies #scientificresearch

27

1 Comment

Happy Monday all! Check out this open access Nature Genetics article by Reed et al., "A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast." Abstract: Here we use single-cell RNA sequencing to compile a human breast cell atlas assembled from 55 donors that had undergone reduction mammoplasties or risk reduction mastectomies. From more than 800,000 cells we identified 41 cell subclusters across the epithelial, immune and stromal compartments. The contribution of these different clusters varied according to the natural history of the tissue. Age, parity and germline mutations, known to modulate the risk of developing breast cancer, affected the homeostatic cellular state of the breast in different ways. We found that immune cells from BRCA1 or BRCA2 carriers had a distinct gene expression signature indicative of potential immune exhaustion, which was validated by immunohistochemistry. This suggests that immune-escape mechanisms could manifest in non-cancerous tissues very early during tumor initiation. This atlas is a rich resource that can be used to inform novel approaches for early detection and prevention of breast cancer. #drugdiscovery #immunooncology #cancerresearch #immunotherapy #breastcancer #oncology #scientificresearch

9

Seeking some thought-provoking reading material post-Thanksgiving? Discover Alcami's proficiency in crafting and conducting microbial challenge in-use studies across various product categories. Our whitepaper delves into the current regulatory expectations, stringent testing methods, and thorough evaluation techniques. 📄 What you’ll learn: 🔹The growing regulatory demands for microbial challenge in-use studies concerning parenteral drug products. 🔹The dangers of microbial contamination during drug handling and the critical role these studies play in ensuring patient safety and meeting regulatory standards. 🔹How these studies replicate real-world scenarios to deliver essential data for product development and safe usage guidance. Download the whitepaper now 👉 https://gag.gl/vETCp0 #Pharma #Biotech #RegulatoryCompliance #QualityControl

7

Check out this new eBook on the new approaches to #CellTherapy authored by Aimee Chiavario

4

Thanks to Miranda Schmalfuhs at Pharmaceutical Executive for doing this in-depth interview with Dotmatics chief product officer, Kalim Saliba talking about the transformative power of Luma Lab Connect for scientific R&D labs who have been increasingly drowning in the ever growing pool of data. Really insightful look at how its benefiting our customers already as they connect hundreds of instruments in their labs to one platform to ingest, organize, model, and analyze. https://lnkd.in/d8xVKaUC

22

1 Comment

Every day our customers surprise us with new ways to do more advanced tests in a POC format. Please read this new blog post: Key breakthroughs in molecular POC testing Learn more about the emerging technologies used and the sample preparation techniques that are key to ensuring their success. Learn more: https://lnkd.in/e4qQB4a6

14

Looking to squeeze in some learning before Turkey Day? Watch our on-demand webinar describing antibody binding rate constant determination on live cells, in-solution using 1-hour assays.

1